There’s a short window of opportunity for COVID-19 free-to-consumer vaccines. home test kits for COVID-19 and certain treatments.
The White House announced this month that the nationwide medical emergency which was first announced in the early 2020s in reaction to the pandemic is scheduled to end on May 11. If it is declared to be over, so will many of the measures created to fight the spread of the virus.
COVID vaccine makers are set to increase prices
Get vaccinations. Up to now it has bought COVID-19 shots. The government recently purchased more than 105 million doses of the bivalent booster from Pfizer BioNTech for around $30.48 for a dose. It also purchased the Moderna version of 66 million doses cost $26.36 each. (These were among the firms who developed some of the initial COVID vaccines available within the United States.)
The public will be able to take these vaccines for a minimal or even free for as long as the supplies purchased by the government are available. Even before the final date for the public health emergency was established, Congress opted not to give more money to boost the stock of vaccines that are in decline by the government. In the end, Pfizer and Moderna had already begun contemplating their entry into the market for commercial products. Both have said that if that happens, they’ll raise their prices around the region of $110-$130 per dose, although insurance companies and health plans of the government might be able to negotiate lower rates.
“We have a double-digit billion [dollar]market opportunity” investors were informed at the JPMorgan event at San Francisco recently by Ryan Richardson who is the chief strategist for BioNTech. BioNTech expects to sell an average price — that is, the total price , including discountsof $110 per dose and, Richardson said, “is much more than reasonable from a health economics standpoint.”
This could result in hundreds of billions of dollars in earnings for manufacturers even if the use of the vaccines isn’t as rapid. Consumers would pay the bill whether directly (in the form of copays) and indirectly (through more expensive premiums and tax-funded subsidies).
Half of adultsapproximately the same amount that get the annual flu shotreceive a COVID vaccine at the current, more expensive cost, a new research by the KFF found that insurance companies and employers, as well as other payors would pay $12.4 billion to $14.8 billion. This is almost double the amount it would have cost each person living in the U.S. to get a bivalent booster at the median cost paid to the Federal government.
For COVID treatment options, an August blog article from the Department of Health and Human Services’ Administration for Strategic Preparedness and Response stated that the government’s drugs Paxlovidare likely to last for at least mid-year, until the private sector is able to take over. The bulk purchase price for the government from the manufacturer Pfizer is $530 per the course of treatment. It isn’t clear what businesses will be charging once the supply from the government runs out.
The kind of health insurance that you’re carrying will affect the amount you’ll have to pay.
One thing is for certain how much the amount, if any, of the increased costs are transferred to consumers will be contingent on their health insurance.
Medicare beneficiaries, people enrolled within Medicaid (the federal state health insurance program that is available to people with low incomes and people with health insurance through those on the Affordable Care Act exchanges will continue to receive COVID-19 vaccinations free of charge, even after an emergency in public health ceases and the vaccines that are purchased by the government go out. People who have insurance through their job will not have to pay the cost of vaccines except if they are out of network for their vaccines.
Patients with limited benefits or insurance policies that are short-term may have be able to cover all or a portion of their vaccines. For those who do not have insurance must pay the full cost out of pocket or take advantage of free or low-cost vaccines through health clinics in the community or other health care providers. If they can’t find a low or free alternative, some non-insured patients might feel pressured to not take vaccinations or undergo testing.
The process of figuring out what might be a hundred dollars or more for vaccinations is particularly difficult “if you’re uninsured or underinsured. That’s why the price increases could cause more gaps,” said Sean Robbins the executive vice president of external affairs at the Blue Cross Blue Shield Association. These increases, he explained will also impact those who are insured, as the cost “flow through the premiums.”
COVID-19 treatments cost more also.
In the meantime, experts from public policy claim that many private insurance providers will continue to offer Paxlovid but patients will be required to pay a copayment at the very least, until they reach their deductible. This is similar to what they would for other prescriptions. Medicaid continues to provide coverage at no charges to patients until 2024.
Medicare beneficiaries will have to pay costs-sharing for the majority of COVID-19 treatments when the emergency ends officially and the government’s supply is exhausted. The treatment must also undergo the standard FDA approval procedure, which is more time-consuming than the emergency permission under which it was promoted
Another issue is that the numbers of uninsured people are expected to rise in the coming year, as states are poised to reintroduce the practice of frequently reviewing Medicaid eligibility this type of evaluation was suspended in the midst of the pandemic. Beginning in April States will start reviewing the extent to which Medicaid enrollees have income or other requirements for eligibility.
A range of 5 or 14 million individuals across the nation could be unable to get coverage.
“This is our number. #1 concern” currently”, declared John Baackes the director of L.A. Care, the largest health plan that is operated by a public plan, with 2.7 millions members.
“They might not be aware that the coverage has been cut off until they fill prescriptions” or seek medical treatment, such as vaccinations, he explained.
Home COVID tests won’t come cost-free for a lot of people.
Rules are in effect for insurance companies which include Medicare as well as Affordable Care Act plans, to pay for up to eight tests per month for each member of the plan until the health emergency in the public sector is over.
For those who are consumers, even those who do not have insurancethe government website has been offering as many as four tests per household until they are exhausted. The Biden administration changed its funding plan in order to buy additional kit and put them up for sale in December, but only until the end of the month.
Beginning in May the beneficiaries of the original Medicare as well as many who have private, work-based insurance will need to begin making out-of-pocket payments for the antigen tests. Certain Medicare Advantage policies, which offer an alternative to Medicare may decide to cover them with copayments. Policies may differ and you should consult your insurance provider. Additionally, Medicaid enrollees will continue to receive test kits at no cost until the middle of 2024.
The direction of COVID tests, treatments and vaccines will be a reflection of the complex mix of insurance coverage that consumers have to access other forms of health care.
“From an individual perspective the vaccines will remain cost-free, but for treatment and test kits many people will be required to pay for it,” said Jen Kates the executive vice-president at KFF. “We’re going back to what was universal access and saying that we’re going back to the same system that is used in the standard U.S. health system.”
KHN reporter Darius Tahir contributed to this report. KHN (Kaiser Health News) is a major independent, independent editorial program of KFF (Kaiser Family Foundation).
Copyright 2023 Kaiser Health News. To see more, visit Kaiser Health News.9(MDEwMjQ0ODM1MDEzNDk4MTEzNjU3NTRhYg004))
